News Image

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Provided By GlobeNewswire

Last update: Jan 8, 2025

-- Approximately $50.0 million of net revenue from sales of LUMRYZ™ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 --

Read more at globenewswire.com

AVADEL PHARMACEUTICALS

NASDAQ:AVDL (12/19/2025, 4:30:07 PM)

After market: 21.47 0 (0%)

21.47

+0.05 (+0.23%)



Find more stocks in the Stock Screener

AVDL Latest News and Analysis

Follow ChartMill for more